S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
New York lawmakers pass $237 billion budget with policies to jump-start housing market
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
New York lawmakers pass $237 billion budget with policies to jump-start housing market
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
New York lawmakers pass $237 billion budget with policies to jump-start housing market
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
New York lawmakers pass $237 billion budget with policies to jump-start housing market
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis

Revolution Medicines (RVMD) Stock Price, News & Analysis

$34.92
-0.91 (-2.54%)
(As of 04/19/2024 ET)
Today's Range
$34.23
$36.37
50-Day Range
$29.00
$37.41
52-Week Range
$15.44
$38.73
Volume
1.24 million shs
Average Volume
1.25 million shs
Market Capitalization
$5.75 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$41.20

Revolution Medicines MarketRank™ Stock Analysis

Analyst Rating
Buy
3.10 Rating Score
Upside/​Downside
18.0% Upside
$41.20 Price Target
Short Interest
Healthy
7.29% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.81
Upright™ Environmental Score
News Sentiment
0.66mentions of Revolution Medicines in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$671,249 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($3.18) to ($3.40) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.31 out of 5 stars

Medical Sector

126th out of 909 stocks

Biological Products, Except Diagnostic Industry

16th out of 149 stocks

RVMD stock logo

About Revolution Medicines Stock (NASDAQ:RVMD)

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

RVMD Stock Price History

RVMD Stock News Headlines

Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
Revolution Medicines (NASDAQ:RVMD) Shares Gap Up to $32.99
RVMD Apr 2024 36.000 call
RVMD Apr 2024 33.000 put
See More Headlines
Receive RVMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Revolution Medicines and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/26/2024
Today
4/21/2024
Next Earnings (Estimated)
5/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:RVMD
Fax
N/A
Employees
378
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$41.20
High Stock Price Target
$48.00
Low Stock Price Target
$28.00
Potential Upside/Downside
+18.0%
Consensus Rating
Buy
Rating Score (0-4)
3.10
Research Coverage
10 Analysts

Profitability

Net Income
$-436,370,000.00
Pretax Margin
-3,798.71%

Debt

Sales & Book Value

Annual Sales
$11.58 million
Book Value
$11.09 per share

Miscellaneous

Free Float
150,691,000
Market Cap
$5.75 billion
Optionable
Optionable
Beta
1.54
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives


RVMD Stock Analysis - Frequently Asked Questions

Should I buy or sell Revolution Medicines stock right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Revolution Medicines in the last twelve months. There are currently 9 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RVMD shares.
View RVMD analyst ratings
or view top-rated stocks.

What is Revolution Medicines' stock price target for 2024?

10 Wall Street research analysts have issued 12 month target prices for Revolution Medicines' shares. Their RVMD share price targets range from $28.00 to $48.00. On average, they expect the company's stock price to reach $41.20 in the next twelve months. This suggests a possible upside of 18.0% from the stock's current price.
View analysts price targets for RVMD
or view top-rated stocks among Wall Street analysts.

How have RVMD shares performed in 2024?

Revolution Medicines' stock was trading at $28.68 at the beginning of 2024. Since then, RVMD stock has increased by 21.8% and is now trading at $34.92.
View the best growth stocks for 2024 here
.

Are investors shorting Revolution Medicines?

Revolution Medicines saw a drop in short interest in the month of March. As of March 31st, there was short interest totaling 12,000,000 shares, a drop of 26.8% from the March 15th total of 16,400,000 shares. Based on an average daily volume of 1,350,000 shares, the days-to-cover ratio is presently 8.9 days.
View Revolution Medicines' Short Interest
.

When is Revolution Medicines' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our RVMD earnings forecast
.

How were Revolution Medicines' earnings last quarter?

Revolution Medicines, Inc. (NASDAQ:RVMD) posted its quarterly earnings results on Monday, February, 26th. The company reported ($1.14) earnings per share for the quarter, missing the consensus estimate of ($0.85) by $0.29. The company earned $0.74 million during the quarter, compared to analysts' expectations of $1.20 million. The company's revenue for the quarter was down 95.2% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.63) earnings per share.

What other stocks do shareholders of Revolution Medicines own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Revolution Medicines investors own include Alector (ALEC), Editas Medicine (EDIT), Homology Medicines (FIXX), Gossamer Bio (GOSS), Livongo Health (LVGO), Sorrento Therapeutics (SRNE), Black Diamond Therapeutics (BDTX), Beam Therapeutics (BEAM), CrowdStrike (CRWD) and Precision BioSciences (DTIL).

When did Revolution Medicines IPO?

Revolution Medicines (RVMD) raised $150 million in an initial public offering (IPO) on Thursday, February 13th 2020. The company issued 10,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Cowen, SVB Leerink and Guggenheim Securities served as the underwriters for the IPO.

Who are Revolution Medicines' major shareholders?

Revolution Medicines' stock is owned by many different institutional and retail investors. Top institutional investors include Mass General Brigham Inc (0.21%) and Allspring Global Investments Holdings LLC (0.00%). Insiders that own company stock include Anthony W Boor, Barbara Weber, Jack Anders, Jeanna Steele, Jeff Cislini, Lorence H Kim, Margaret A Horn, Mark A Goldsmith, Peter Svennilson, Rock Ventures Ii LP Third, Rock Ventures Iii LP Third, Stephen Michael Kelsey, Sushil Patel, Thilo Schroeder and Xiaolin Wang.
View institutional ownership trends
.

How do I buy shares of Revolution Medicines?

Shares of RVMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:RVMD) was last updated on 4/21/2024 by MarketBeat.com Staff

From Our Partners